by Marisa Wexler, MS | Apr 21, 2026 | Myeloma News
The U.S. Food and Drug Administration (FDA) has granted fast track status to Opna Bio‘s OPN-6602 as a potential treatment for people with multiple myeloma that has come back or failed to respond following at least four prior lines of therapy. The new designation was...
by MM360 Staff | Apr 21, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by MM360 Staff | Apr 21, 2026 | Publications
EClinicalMedicine. 2026 Apr 6;94:103868. doi: 10.1016/j.eclinm.2026.103868. eCollection 2026 Apr. ABSTRACT BACKGROUND: Bone-marrow minimal residual disease (MRD) and positron emission tomography/computed tomography (PET-CT) are central to response assessment in...
by Marisa Wexler, MS | Apr 20, 2026 | Myeloma News
AML World Awareness Day, an annual effort to educate people about acute myeloid leukemia (AML), is coming up on April 21, and the advocacy group Know AML — comprised of member organizations from the Americas to Europe, Africa, Asia and Oceania — is marking the day...
by Marisa Wexler, MS | Apr 17, 2026 | Myeloma News
Most people with previously-treated metastatic pancreatic cancer lived for at least one year after receiving the oral therapy candidate daraxonrasib in a clinical trial — a result that daraxonrasib’s developer Revolution Medicines described as an “unprecedented...
